Statement From AquaBounty Technologies, Inc.

AquaBounty Technologies, Inc. (“AquaBounty” or “the Company”) 
FDA Approves AquAdvantage® Salmon 

MAYNARD, Massachusetts, 19 November 2015 – AquaBounty Technologies, Inc. (AIM: ABTU; OTC: AQBT), a biotechnology company focused on enhancing productivity in aquaculture, and a majorityowned subsidiary of Intrexon Corporation (NYSE: XON), announces today that the U.S. Food and Drug Administration (FDA) has approved the Company’s New Animal Drug Application for the production, sale, and consumption of its AquAdvantage® Salmon, an Atlantic salmon that has been genetically enhanced to reach market size in less time than conventional farmed Atlantic salmon.


Ronald L. Stotish, Ph.D., Chief Executive Officer of AquaBounty, commented, “AquAdvantage Salmon is a game-changer that brings healthy and nutritious food to consumers in an environmentally responsible manner without damaging the ocean and other marine habitats. Using land-based aquaculture systems, this rich source of protein and other nutrients can be farmed close to major consumer markets in a more sustainable manner.”

The U.S. currently imports over 90% of all the seafood, and more specifically over 95% of the Atlantic salmon, it consumes. AquAdvantage Salmon will offer the opportunity for an economically viable domestic aquaculture industry while providing consumers a fresh and delicious product.

Through greater efficiency and localized production, AquaBounty’s AquAdvantage Salmon increases productivity while reducing costs and the environmental impacts associated with current salmon farming operations. Land-based aquaculture systems can provide a continuous supply of fresh, safe, traceable, and sustainable AquAdvantage Salmon to communities across the U.S. and do it with a reduced carbon footprint. Importantly, it offers an alternative approach to fish farming that does not exploit the oceans.

Jack A. Bobo, Senior Vice President and Chief Communications Officer at Intrexon, stated, “The U.S. Dietary Guidelines Advisory Committee encourages Americans to eat a wide variety of seafood— including wild caught and farmed—as part of a healthy diet rich in healthy fatty acids. However, this must occur in an environmentally friendly and sustainable manner. FDA’s approval of the AquAdvantage Salmon is an important step in this direction.

About AquaBounty Technologies. Inc.

AquaBounty Technologies, Inc. is a publicly traded company whose largest shareholder is Intrexon Corporation (NYSE: XON). Intrexon is a synthetic biology company with diverse interests in medicine, food and agriculture, and fuels and the environment. AquaBounty is an aquaculture company focused on improving productivity in commercial aquaculture, a $144 billion industry and the fastest-growing segment of the worldwide food industry. The Company’s objective is the application of biotechnology to ensure the availability of high quality seafood to meet global consumer demand. AquaBounty is developing products to address critical production constraints in the most popular farmed species, focusing initially on salmon, trout, and tilapia. Its AquAdvantage® fish program is based upon a single, specific molecular modification in fish that results in more rapid growth in early development.

Safe Harbor Statement

Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives, and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives, and expectations expressed in this press release.

For more information, please contact:

Dave Conley 
Director of Communications 
AquaBounty Technologies, Inc. 
Tel: +1 (613) 294-3078 
dconley@aquabounty.com

4 Steps to Shedding Your Pandemic Pounds

Forgive yourself, and start walking toward a healthier you.

For those of you who have put on the Pandemic Pounds or added several new COVID Curves, you are not alone. Alarmingly, the American Psychological Association has recently published that almost half of all adults in their survey now have a larger physique. In fact, 42% of people reported gaining roughly 15 pounds (the average published was surprisingly 29 pounds but that included outliers) over the past year. Interestingly, 20% of adults in this survey lost about 12 pounds (I am surely not in this group). Clearly, there is a relationship between stress and weight change. In addition, one in four adults disclosed an increase in alcohol consumption, and 67% of participants distressingly revealed that they have new sleeping patterns.

This past year has brought about what has been called the 'new normal.' Social isolation and inactivity due to quarantining and remote working have sadly contributed to the decline in many people's mental and physical health, as demonstrated by the widespread changes in people's weight, alcohol consumption, and sleeping patterns. Gym closures, frequent ordering of unhealthy takeout, and increased time at home cooking and devouring comfort foods have had a perceptible impact. In addition, many people have delayed routine medical care and screening tests over fear of contracting Covid-19 during these visits. Unfortunately, the 'new normal' has now placed too many people at risk for serious health consequences, including heart attacks and strokes.

Keep Reading Show less